Next Article in Journal
Combination of Niclosamide and Pirfenidone Alleviates Pulmonary Fibrosis by Inhibiting Oxidative Stress and MAPK/Nf-κB and STATs Regulated Genes
Next Article in Special Issue
[212Pb]Pb-eSOMA-01: A Promising Radioligand for Targeted Alpha Therapy of Neuroendocrine Tumors
Previous Article in Journal
Influence of Bifidobacterium breve on the Glycaemic Control, Lipid Profile and Microbiome of Type 2 Diabetic Subjects: A Preliminary Randomized Clinical Trial
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Pharmaceuticals
Volume 16
Issue 5
10.3390/ph16050696
pharmaceuticals-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Validation of Freshly Isolated Rat Renal Cells as a Tool for Preclinical Assessment of Radiolabeled Receptor-Specific Peptide Uptake in the Kidney

by
Pavel Barta
1,
Petr Nachtigal
2,
Jana Maixnerova
3,
Lenka Zemankova
4 and
Frantisek Trejtnar
3,*
1
Department of Biophysics and Physical Chemistry, Faculty of Pharmacy in Hradec Kralové, Charles University, Akademika Heyrovskeho 1203, 50005 Hradec Kralove, Czech Republic
2
Department of Biological and Medical Sciences, Faculty of Pharmacy in Hradec Kralové, Charles University, Akademika Heyrovskeho 1203, 50005 Hradec Kralove, Czech Republic
3
Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Kralové, Charles University, Akademika Heyrovskeho 1203, 50005 Hradec Kralove, Czech Republic
4
Department of Cell Biology and Genetics, Faculty of Science, Palacky University, Slechtitelu 27, 78371 Olomouc, Czech Republic
*
Author to whom correspondence should be addressed.
Pharmaceuticals 2023, 16(5), 696; https://doi.org/10.3390/ph16050696
Submission received: 27 February 2023 / Revised: 19 April 2023 / Accepted: 2 May 2023 / Published: 4 May 2023
(This article belongs to the Special Issue Development of Radiolabeled Peptides)
Browse Figures
Versions Notes

Abstract

:
The synthetic analogs of regulatory peptides radiolabeled with adequate radionuclides are perspective tools in nuclear medicine. However, undesirable uptake and retention in the kidney limit their application. Specific in vitro methods are used to evaluate undesirable renal accumulation. Therefore, we investigated the usefulness of freshly isolated rat renal cells for evaluating renal cellular uptake of receptor-specific peptide analogs. Special attention was given to megalin as this transport system is an important contributor to the active renal uptake of the peptides. Freshly isolated renal cells were obtained from native rat kidneys by the collagenase method. Compounds with known accumulation in renal cells were used to verify the viability of cellular transport systems. Megalin expressions in isolated rat renal cells were compared to two other potential renal cell models by Western blotting. Specific tubular cell markers were used to confirm the presence of proximal tubular cells expressing megalin in isolated rat renal cell preparations by immunohistochemistry. Colocalization experiments on isolated rat kidney cells confirmed the presence of proximal tubular cells bearing megalin in preparations. The applicability of the method was tested by an accumulation study with several analogs of somatostatin and gastrin labeled with indium-111 or lutetium-177. Therefore, isolated rat renal cells may be an effective screening tool for in vitro analyses of renal uptake and comparative renal accumulation studies of radiolabeled peptides or other radiolabeled compounds with potential nephrotoxicity.

Graphical Abstract

1. Introduction

The radiolabeled analogs of several regulatory peptides are perspective tools for scintigraphic radioimaging or for the radiotherapy of some malignancies [1,2]. Investigations have focused on radiolabeled somatostatin analogs and gastrin derivatives such as minigastrins (MG) [3,4]. Preclinical and clinical studies have evaluated compounds derived from octreotide or gastrin radiolabeled with various radionuclides and tested them as potential radiodiagnostic agents. Many analogical somatostatin or minigastrin analogs radiolabeled with beta-emitting radionuclides have been investigated as tools for treating patients with receptor-positive tumors [3,4]. However, the significant renal uptake of radiolabeled peptide analogs [5,6] may reduce the ability to detect small tumors in the perirenal region by scintigraphic imaging. It may also result in radiotoxicological injury to the kidney, limiting the peptides’ clinical use [7].
Several experimental models can be used to study renal transport, accumulation, and the retention of compounds in vitro. These models include isolated kidneys, precision-cut tissue, or cells. Various standard cell lines representing renal epithelial cells are particularly applicable to biomedical research. For example, OK (opossum kidney) cells, LLC-PK1 (porcine kidney) cells, MDCK (Madin–Darby canine kidney) cells, and HK2 (human kidney) cells are commercially available as renal in vitro models. OK cells and rat yolk sac epithelial cells have been used as cellular models in studies on the renal handling of radiolabeled peptides in vitro [8,9]. However, other cell types may also be viable for biomedical research. Such models may represent primary proximal tubular cells [10] or native renal cells freshly prepared from the animal kidney [11] immediately before transport studies. The established renal cell models differ in basic biochemical function parameters [12]; however, they also differ in the expression of drug transporters in the cellular membrane. Nevertheless, comparative studies on the differences in individual cell renal models’ membrane drug transporters are still scarce. Therefore, evaluations and comparisons of the usefulness of renal cellular models for particular groups of drugs and study types are necessary. In addition, other characteristics of the available renal cellular models should be investigated more thoroughly.
Renal accumulation is mediated by several transport mechanisms depending on many factors, such as molecular size, charge, and lipophilicity. Transporters localized at renal proximal tubular cell membranes, such as OATs (organic anion transporters) or OCTs (organic cation transporters), are responsible for the influx of organic anions or cations into renal cells with a relatively lower molecular size [13]. Larger peptides and proteins are transported from the urine by the multi-ligand endocytic megalin receptor complex localized at the apical membrane of the proximal renal tubules. Megalin (LRP2) is a large glycoprotein, a member of the low-density lipoprotein receptor family, and is abundantly expressed in the proximal kidney tubules and several other absorptive epithelia [14,15]. The megalin system mediates the transport of peptides and proteins such as albumin, plasminogen, polybasic drugs, or low-molecular-weight polypeptides such as insulin and angiotensin II [16]. This transport system plays an important role in the renal uptake of many radiopeptides that are potentially useful as radiodiagnostics or radiotherapeutics [5,7,9].
The present study examines the applicability of freshly isolated rat renal cells to transport and accumulation studies. It also considers the difficulties encountered in such studies. The value of primary renal cells for testing radiopeptide renal uptake and differences in megalin expression in several cellular renal models were evaluated. Several radiolabeled somatostatin and gastrin analogs labeled with indium-111 or lutetium-177 were employed as radiopeptide representatives. These compounds are known to accumulate to varying degrees in kidney tissue [5,6]. We used several radiolabeled compounds with known renal uptake to validate the transport functions of the prepared cells. Radiolabeled albumin and DMSA (dimercaptosuccinate) were selected as markers of proximal tubule endocytic activity. Both compounds are known as substrates of the megalin endocytic receptor [14,17]. [99mTc]Tc-MAG3 (mercaptoacetylglycylglycylglycine) is transported into renal cells via an energy-dependent transport system for organic anions [18]. Therefore, its cellular uptake indicates the adequate energetic state of kidney cells and the integrity of cell membranes. To assess the method’s validity and compare our findings with previously published results, we compared megalin expression in cell models with native kidney tissue. We used immunochemistry to demonstrate proximal renal cells bearing megalin in experimental preparations of isolated rat renal cells.

2. Results

2.1. Megalin Expression Approvement

The Western blot analysis confirmed the expression of the megalin endocytic receptor in the studied cells and tissues. LLC-PK1 and isolated rat cells showed considerable expression, whereas the megalin detection in OK cells was unsuccessful. A strong expression was also found in the comparative preparations of porcine and rat kidney cells, as well as in JEG-3 human placental cells, which served as a positive control (Figure 1).
Fluorescence immunohistochemistry using specific markers of proximal tubules and distal tubules, PHA-E and PNA, confirmed the colocalization of megalin and PHA-E exclusively in the proximal tubules of the rat kidney (Figure 2). Moreover, the same colocalization was visible in isolated rat kidney cells (Figure 3). On the contrary, no colocalization of megalin or PNA in the distal tubules was detected in the rat kidney (Figure 4). The results of the immunohistochemical analysis clearly demonstrated megalin colocalization with proximal tubule markers (PHA-E) only, both in the rat kidney and rat kidney cells.

2.2. Evaluation of Cell Uptake In Vitro

The cellular accumulation of two somatostatin receptor-specific analogs ([111In]In -DOTA-TATE and [111In]In -DOTA-NOC) was compared in two renal cellular models, OK cells and LLC-PK1 cells. Our results showed that cellular uptake following an incubation period of 30 min was relatively similar in both cell lines for [111In]In -DOTA-TATE (Figure 5). However, the [111In]In -DOTA-NOC accumulation observed in LLC-PK1 cells was significantly higher than that in OK cells (Figure 5).
Several radiolabeled peptides were incubated with isolated rat renal cells to compare their cellular retention. The results document different degrees of cell uptake (Table 1). The data on radiopeptide cellular uptake were compared with already available data on radiopeptide renal retention in rats in vivo, which were previously published by our team. The in vivo data show radioactivity in the kidneys 60 min after i.v. administration (Table 1). The tested somatostatin analogs generally exhibited a higher cell uptake in the isolated rat renal cells in comparison to the evaluated radiolabeled gastrin derivatives. [111In]In-DOTA-MG0 is the only exclusion among the tested minigastrins because its cellular accumulation is considerably high. The obtained data are in good accordance with previously published in vivo results. [111In]In-DOTA-MG0 retention in the rat kidney is relatively high, whereas renal retention of the other [111In]In-minigastrins is very low. Radiolabeled somatostatin analogs accumulate in the kidney in vivo relatively more intensively than most 111In-DOTA-minigastrins (Table 1).
Another experiment tested renal cellular models’ usefulness in studying the active mechanisms of renal accumulation. The results presented in Figure 6 show that isolated rat renal cells can be used to compare the contribution of active membrane processes to the cellular accumulation of selected radiolabeled compounds. Generally, the obtained results confirmed the preservation of transport mechanisms in the isolated renal cells. The highest contribution of active accumulation to cell uptake was found in [99mTc]Tc-MAG3. Only a negligible accumulation was observed in this compound at the low incubation temperature, which blocked active processes. The lowest contribution of active uptake to total accumulation was observed in [99mTc]Tc-DMSA. The compound was accumulated predominantly by passive transport mechanisms. The tested radiolabeled peptides exhibited a relatively high participation of active transport processes in the total cell accumulation.
The experiment evaluating the influence of the cells’ growth period on the cellular uptake rate showed that [99mTc]Tc-albumin accumulation by endocytosis was significantly lower in cells grown in a shorter time interval. Table 1 documents this finding for LLC-PK1 cells that grew for 6 h and for 3 days. A comparison of the uptake of 99mTc-albumin in the two renal cell types revealed a significant difference in the cellular uptake between isolated rat renal cells and the LLC-PK1 cell line (Table 2).

3. Discussion

Cell lines are used extensively in biomedical research as in vitro models for kidney tissue. The validity of the data obtained in such experiments depends on the quality of the cell line, particularly when used as a surrogate for the tissue of origin. However, the typical parameters of cell lines may change due to various factors, and authentic characteristics may be lost [22]. Cell lines commonly used as in vitro models in biomedical studies can be unintentionally swapped, contaminated, or mutated. Any of these occurrences may result in different cellular parameter variations, including the amount of transport membrane proteins. In most cases, the cell lines lose transport expression to a significant extent. Drug transporters expressed in cell lines originating from relevant organs (e.g., kidney, liver, and intestine) may differ quantitatively and qualitatively from natural tissue [23,24]. Therefore, natural/primary cellular models should be considered for confirmation studies.
Freshly isolated cells may have advantages over renal cell lines; e.g., they exert similar functions to natural cells. In addition, according to a recently published interspecies comparison, rats appear to be the most suitable species for studying renal retention of radiolabeled peptides [6]. On the other hand, the complicated preparation and limited amount of cells available from one animal could be considered disadvantages of the method. Compared to conventional cell lines, performing the experiment is more demanding on the skill of the staff and the coordination of the experimental work. Another disadvantage of freshly isolated cells compared to standard cell lines is the limited lifespan of the cells. Therefore, the method is not suitable for studying the long-term accumulation of substances. Because the method includes the use of rat cells, interspecies differences should be considered. However, there is no relevant information on differences between rat and human megalin systems concerning peptide transport. The preparation of isolated renal cells contains a mixture of renal cell populations. However, this does not impede comparative studies on renal drug transport. In such cases, the renal preparation represents the kidney as a whole organ; thus, the accumulation could represent total renal uptake. It is necessary to use a separation method such as flow cytometry or centrifugation to identify which cell type is responsible for renal uptake. According to known data on transporter localization in the nephron [13], we can generally expect the most intensive drug uptake in renal proximal tubular cells.
Freshly isolated rat renal cells have been used in toxicological in vitro studies [25,26,27], physiological in vitro studies [28,29], metabolic phenotyping [30], and experimental studies on drug metabolism [31,32]. Although experimental studies on peptide accumulation in the kidney may be successfully performed in vitro using selected cell lines, such as OK (opossum kidney) cells [8], isolated rat renal cells might also help analyze the renal handling of xenobiotics, including radiolabeled compounds [33]. This method may apply to radiolabeled peptides that are potentially useful in radiodiagnosis and targeted radiotherapy, such as somatostatin analogs, since they are, in most cases, excreted from the body via the kidney [5,9]. Therefore, radiopeptide concentrations in the urine and kidney may be relatively high. This pharmacokinetic characteristic is the basis for undesirable renal uptake and the retention of radiolabeled peptides. Furthermore, radioactive accumulation in the patient’s kidney may lead to the radiotoxic damage of the renal tissue [9,34].
To assess the mechanism and renal uptake rate of the model peptides, comparing their accumulation rate to the uptake of compounds with known renal accumulation and transport mechanisms into cells is useful. For example, albumin may serve as a reliable marker of active endocytosis. Albumin is intensively reabsorbed in the proximal renal tubules and transported into renal cells by megalin-mediated endocytosis. Therefore, the compound is a common substrate of this endocytic receptor [35,36]. Similarly, [99mTc]Tc-DMSA accumulates in the kidneys via megalin-mediated endocytosis [17]. The renal accumulation of [99mTc]Tc-DMSA significantly depends on retaining megalin receptor function. Therefore, it can serve as a marker of proximal tubule endocytic activity. Highly accumulated experimental compounds can be compared quantitatively with [99mTc]Tc-MAG3 renal uptake. This agent is a compound that accumulates intensively in renal tissue and cells via an active transport system for organic anions [18].
Accumulation studies with several radiolabeled peptides were conducted to compare the usefulness of isolated rat renal cells for in vitro transport studies. We used both this model and selected standard renal cell lines. The obtained experimental data suggest different renal uptake rates in individual renal cellular models. LLC-PK1 cells showed similar uptake in one radiopeptide but significantly different uptake in another. In addition, the 99mTc-albumin active uptake was significantly higher in isolated rat renal cells than in LLC-PK1 cells. Such experimental data document that several renal cellular models may be advisable for renal transport and receptor-specific radiopeptide accumulation studies. The relatively high retention of 99mTc-MAG3 and 99mTc-albumin in isolated rat cells confirms the cells’ good metabolic state and maintenance of transport function throughout the time interval used.
One problem with using in vitro cellular models is the variable expression of cellular components during passaging and growing. Variations in CYP450 isoenzyme activity in cell lines used to study biotransformation processes have been well described [37]. Similarly, drug membrane transporters may be expressed differently in cell lines depending on the origin or culture conditions [38,39]. However, such data are very scarce. We demonstrated that, in the case of radiopeptides, in vitro accumulation might be affected by the interval between seeding the cells and the time of the accumulation experiment. This finding means that the transport rate and cellular accumulation may depend on the cell growth phase. Although the time interval for observing differences in transport activity was much longer than for the cell lines, age-related changes in the endocytic receptors megalin and cubilin have been described in rats in vivo [40]. However, this will have only minor significance if experiments with cell lines are conducted under a constant regime and time intervals concerning seeding.
Based on the abovementioned variations in transport system activity, it is important to assess the expression of the studied transporter/s in the cellular model being used. We used Western blotting to analyze megalin expression in renal cellular models. Moreover, we compared megalin expression in both cells and kidney tissue. This analysis confirmed the presence of megalin endocytic receptors in the studied cells and tissues. LLC-PK1 cells and isolated rat renal cells showed considerable expression, whereas megalin detection in OK cells was unsuccessful. Strong expression was also found in comparative porcine and rat kidney preparations and in JEG-3 human placental cells. Such findings align with known data showing that the placenta and the tubular renal epithelium are two locations exhibiting significant megalin expression [36,41].
In our experiment, the most probable explanation for our inability to confirm megalin expression in OK cells was the specificity of the anti-megalin antibody used. The antibody is intended for use in human and rat tissue; thus, it reacts with human and rat megalin but not with opossum kidney protein. Since an anti-megalin antibody for opossum use is unavailable, commercially available opossum kidney cells present a relative disadvantage compared to rat and human renal cells regarding megalin detection by blotting.
The results of the immunohistochemical analysis in isolated rat kidney cells demonstrated megalin colocalization using biochemical markers in the proximal tubular cells. These indicators are found specifically in the proximal cell membrane. We did not see any significant megalin colocalization using markers in distal tubular cells. Megalin, the receptor responsible for active endocytosis, was expressed in both isolated rat renal cells and LLC-PK1 cells. These findings agree with previous reports on megalin localization in renal tissue and renal epithelium [36,42].
The presented study is focused on a possible application of the method using isolated rat renal cells in preclinical investigation on new peptide radiopharmaceuticals. Although other structural groups of potential radiopharmaceuticals may also exert an undesirable retention in the kidney [43,44], the renal accumulation of radiopeptides is a particularly interesting research area. Because of the risk of radiotoxicological kidney damage, special precautions must be taken in clinical practice in patients treated with radiolabeled peptides such as somatostatin analogs, which include an infusion of selected amino acids or other protective measures [45]. Moreover, the number of potential radiolabeled receptor-specific peptides under investigation is increasing. The group includes many peptide subgroups focused on various receptor targets. However, the undesirable renal uptake is solved by preclinical studies in many types of radiopeptides [46,47]. Therefore, the renal retention of radiopeptides using a wider range of methods remains an important research issue.

4. Materials and Methods

4.1. Western Blot Analysis

Megalin expression by Western blotting was studied in several types of renal cells (OK cells, LLC-PK1 cells, and freshly isolated rat renal cells) and compared to expressions in rat and porcine native renal tissue and a human placental cell line (JEG-3 cells) that is known to express megalin [48].
The excised rat and porcine kidney tissues were homogenized using Ultra Turrax Tube Drive (IKA, Staufen, Germany) with 10 mmol/L of Tris-HCl, 250 mmol/L of sucrose, 1 mmol/L of EDTA with pH 7.6, 0.5 µg/mL of leupeptin, 2 µg/mL of aprotinin, 50 µg/mL of benzamidine, and 40 µg/mL of phenylmethylsulfonyl fluoride (PMSF). The homogenate was centrifuged at 10,000× g for 60 min at 4 °C [49,50]. The LLC-PK1 and OK cells were grown in a 75 cm2 tissue culture flask and were lysed using a cell lysis buffer containing 0.5% of SDS and 10 mmol/l of Tris/HCl, pH 7.4. It was supplemented with 0.5 µg/mL of leupeptin, 2 µg/mL of aprotinin, 50 µg/mL of benzamidine, and 40 µg/mL of PMSF. The homogenate was centrifuged at 3000 g for 10 min at 4 °C [51,52]. The BCA (bicinchoninic acid) method determined the protein content of the resulting supernatants [53].
A Power Pac HC (BioRad, UK) was used to separate protein extracts for megalin by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) on a 6.25% gel (9 µg protein/lane). The proteins were electrotransferred onto a polyvinylidene (PVDF) membrane (Sigma–Aldrich, St. Louis, MO, USA). The protein transfer was checked routinely by staining the membrane with Ponceau S solution (Serva, Heidelberg, Germany). For immunoblotting, the antibodies were dissolved in 5% low-fat dried milk (BioRad, Hercules, CA, USA) in a Tris-buffered saline solution (TBS) containing 0.05% Tween (Duchefa Biochemie, Haarlem, The Netherlands). The membrane was immunoblotted with rabbit anti-megalin (donated by Prof. D. Biemesderfer, Yale University School of Medicine, New Haven, CT, USA) and mouse anti-β-actin antibodies at dilutions of 1:8000 and 1:5000, respectively. Megalin detection was performed with the appropriate horseradish peroxidase (HRP)-conjugated secondary antibodies at 1:2000 dilution (GE Healthcare, Amersham, UK) and 1:8000 for β-actin (Sigma–Aldrich, St. Louis, MO, USA) and enhanced with a chemiluminescence reagent (Thermo Scientific, Waltham, MA, USA).

4.2. Immunohistochemistry

Phaseolus vulgaris Erythroagglutinin (PHA-E) lectin was used as a specific marker of proximal tubulus, and Peanut Agglutinin (PNA) was used as a specific marker of distal tubules as previously published [54,55].
Rat kidneys were fixed by immersion in 4% neutral formaldehyde for 3 days and embedded in paraffin, after which 6 μm thick sections were cut. The renal rat cells were fixed in a 4% neutral formaldehyde solution for 1 h. They were immersed in OCT (optimal cutting temperature) embedding medium (Leica, Prague, Czech Republic) and then frozen in a freezer and stored at −20 °C. Afterward, serial cross-sections (7 μm) were cut on a cryostat and placed on gelatin-coated slides.
For the double fluorescence staining, we used a goat anti-rabbit secondary antibody marked with a green fluorochrome (CY2) (Jackson Immunoresearch, Suffolk, UK) (diluted at 1/100 in 5% bovine serum albumin (BSA) in phosphate-buffered saline (PBS)) to detect a rabbit anti-megalin antibody (anti-MC-220) at 1/100 dilution in 5% BSA in PBS for 1 h at room temperature. ExtrAvidin®−Cy3™ (Sigma–Aldrich, St. Louis, MO, USA) diluted at 1/500 in 5% BSA in PBS was used to detect either biotinylated Phaseolus Vulgaris Erythroagglutinin (PHA-E–diluted at 1/500 in 5% BSA in PBS; Vector Laboratories, Newark, CA, USA) or biotinylated Peanut Agglutinin (PNA—diluted at 1/500 in 5% BSA in PBS; Vector Laboratories, Newark, CA, USA) in the rat kidney and rat kidney cells. 4′,6-diamidino-2-phenylindole dihydrochloride (DAPI) (Sigma–Aldrich, St. Louis, MO, USA) was used for nuclei staining.
Microscopic photo documentation and image digitizing were performed using the Olympus AX 70 light and fluorescence microscope. We used a VDS Vosskuehler CD-1300QB monochromatic camera for fluorescence along with image analysis software NIS (Laboratory Imaging, Prague, Czech Republic).

4.3. Experiments with the Isolated Rat Renal Cells

Fresh rat renal cells were isolated from the kidney using the two-phase collagenase perfusion method described by Jones et al. [11]. Male Wistar rats weighing 270–330 g were used for the experiments. The rats were housed under standard conditions (tap water, standard diet, and a 12/12 h light–dark cycle). Animals were fasted for 18–24 h prior to experiments. The animal experiments were approved by the Ethical Committee of the Ministry of Education, Czech Republic (approval no. MSMT-7041/2014-11), and complied with Czech laws concerning animal protection.
As a first step, rats were anesthetized (sodium pentobarbital, 50 mg/kg), the abdomen was opened, and the right renal artery and adjacent parts of the aorta were freed. Then, the right renal artery was cannulated via the aorta. Single-pass perfusion was conducted using oxygenated calcium-free Hanks’ buffer (pH 7.4) containing EGTA (0.5 mM) and Hepes (25 mM). The second perfusion phase was performed in a recirculation system with modified Hanks’ buffer containing CaCl2 (4 mM) and collagenase (0.10 % w/v) for 18–22 min. The kidneys were removed and dispersed in cold Krebs–Henseleit buffer with Hepes (25 mM) and bovine serum albumin (2% w/v). The resulting suspension was filtered and washed with Krebs–Henseleit buffer. Following centrifugation (3 min; 80 g; 4 °C), we used the trypan blue exclusion method to determine the number of cells in the suspension. The preparations used had an initial viability of 88–93%. As a result, the cell viability at the end of the 30 min incubation interval was >85%.
Standard incubations were conducted for 30 min at 37 °C using 1 mL of cell suspension containing 2.106/mL renal cells. The radiopeptide uptake was determined by mixing 1 mL of cell suspension and 10 µL of the radiopeptide (1 µg/mL). After incubation, the cells were washed four times and separated. The radioactivity of the cell fractions was measured as mentioned below.
An experiment was arranged to test this cellular model’s potential for investigating active membrane transport processes in radiopeptide renal accumulation. The accumulation rates of [111In]In-DOTA-TATE and [111In]In-DOTA-NOC in isolated renal cells were compared to several compounds with known uptake in renal tubular cells, namely, ([99mTc]Tc-albumin, [99mTc]Tc-MAG3, and [99mTc]Tc-DMSA). Using the same procedure as for the radiopeptides, we tested and expressed the uptake of the other studied compounds. In addition to incubations at 37 °C, experiments at a low incubation temperature (2–4 °C) were performed to compare the role of active transport processes in the renal uptake of the studied agents.

4.4. Radiolabeling of Peptides

[DOTA0, D-Phe1, 1-Nal3]-octreotide (DOTA-NOC), [DOTA0, Tyr3, Thr8]-octreotide (DOTA-TATE), minigastrins (MG) DTPA-MG0 (DTPA-DGlu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2), DOTA-MG11 (DOTA-DGlu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2), DOTA-MG11 (DOTA-DGlu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2), DOTA-MG45 (DOTA-DGln6-Ala-Tyr-Gly-Trp-Nle-Asp-Phe-NH2), and DOTA-MG47 (DOTA-DGln6-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2) were purchased from piCHEM (Graz, Austria). 111InCl3 and 111LuCl3 were purchased from GE Healthcare Ltd. (Amersham, UK) and Perkin Elmer (Boston, MA, USA), respectively. MAG3 (mercaptoacetylglycylglycylglycine) and DMSA (dimercaptosuccinate) were obtained from the Nuclear Research Institute (Rez, Czech Republic).
We prepared DOTA-TATE and DOTA-NOC labeled with 111In using the following method: An amount of 200 μL of 0.4 M acetate buffer (pH 5) with 0.24 M of gentisic acid, 10 μg of peptide in 10 μL of H2O, and 19 MBq of 111InCl3 in 0.04 M HCl were added to a vial. The solution was mixed thoroughly and incubated at 90–95 °C for 25 min. DOTA-TATE and DOTA-NOC labeled with 177Lu were prepared using 30 µL of 0.4 M acetate buffer (pH 5), 3 µg of peptide in 3 µL of H2O, and 46 MBq of 177LuCl3 in 0.05 M HCl. The solution was mixed thoroughly and incubated at 92 °C for 30 min. For somatostatin peptide conjugates, labeling efficiency was determined by instant thin-layer chromatography using 0.1 M of ammonium acetate with 10 mM of EDTA as mobile phase 1 and 10% ammonium hydroxide with methanol as mobile phase 2 (ratio 1:9). Radiochemical purity analysis using HPLC was performed on a column of LiChroCART 125–4 HPLC Cartridge Purospher RP18e at 5 mm (Merck, Darmstadt, Germany) using a Pharmacia LKB system linked to a Gradient Master GP 962 (Institute of Organic Chemistry and Biochemistry, Prague, Czech Republic) and operated with a UV detector and radioactivity monitoring analyzer. Mobile phases A (0.1% TFA in water) and B (CH3CN) were used with the following gradients: 0–5 min 0% B; 5–25 min 0–30% B; 25–30 min 30% B; 30–35 min 30–100% B; 35–40 min 100% B. The flow rate was maintained at 0.5 mL/min. [99mTc]Tc-MAG3 and [99mTc]Tc-DMSA were prepared and assessed according to the manufacturer’s instructions. The [99mTc]Tc-albumin was prepared according to Dekker et al.’s method [56]. A Wallac 1480 Wizard 3” gamma-counter (Wallac, Turku, Finland) measured 111In, 177Lu, and 99mTc activity in the biological samples.
Radiolabeling of minigastrins with 111In was performed by adding about 19 MBq of 111InCl3 in 0.5–1 μL of 50 mM HCl to 50 μL 0.4 M sodium acetate buffer (pH 4.5) with 10 μg of the peptide. After incubating at 80 °C for 30 min, the quality control of the product was determined by a gradient HPLC analysis [21].
A purification step following radiolabeling was not used because the employed procedures resulted in high radiolabeling yields. Radiochemical purity of the radiopeptide preparations was in the range of 97–99%. Specific activity of 111In- and 177Lu-labeled peptide preparations ranged from 1.5–2.5 to 12–15 MBq/µg, respectively. For biological experiments, all radiopeptide solutions were diluted with saline to a concentration of 1 μg/mL.

5. Conclusions

The results of the present study and previous studies suggest that, along with other cellular renal models, isolated rat renal cells might serve as a helpful tool for comparative transport studies and analyses of renal transport mechanisms in radiolabeled peptides and other investigational radiopharmaceuticals. The presented experimental in vitro model can be used not only to quantitative determination of potential renal uptake but also to analyze the contribution of active and passive transport to renal accumulation. The preservation of the main renal transport mechanism for the endocytic uptake of peptides and large proteins, megalin, can be considered an important advantage of the model. Future applications of the method could also include the experimental testing of renal retention in high molecular weight substances with considerable scientific significance such as radiolabeled antibody fragments or aptamers. The established method is also applicable for studies of the renal accumulation of non-radioactive drugs, nanoparticles, and other new drug carriers. Due to certain limitations, combinations with other available cell or organ models may improve the translational potential of the obtained data.

Author Contributions

Conceptualization, F.T. and P.N.; methodology, P.B., F.T. and P.N.; formal analysis, P.B. and P.N.; investigation, P.B., L.Z. and J.M.; resources, J.M.; writing—original draft preparation, F.T.; writing—review and editing, F.T. and P.N.; visualization, P.N. and L.Z.; funding acquisition, F.T. and P.N. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by grants from Charles University, Prague (The Charles University Cooperatio Program “Pharmaceutical Sciences” and SVV 260549).

Institutional Review Board Statement

All animal experiments were performed in accordance with Czech Act No. 246/1992 Coll. for the Protection of Animals against Cruelty, approval no. MSMT-7041/2014-11 (date of approval 10 January 2013) by the Ministry of Education, Czech Republic, and the guidelines of Charles University, Faculty of Pharmacy, for the care and use of animals. This article does not contain any studies with human participants.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Acknowledgments

We would like to express our gratitude to D. Biemesderfer (Yale University School of Medicine, Department of Medicine, New Haven, CT, USA) for donating rabbit anti-megalin antibodies.

Conflicts of Interest

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of the data; in the writing of the manuscript; or in the decision to publish the results.

References

  1. Mohtavinejad, N.; Shafiee Ardestani, M.; Khalaj, A.; Pormohammad, A.; Najafi, R.; Bitarafan-Rajabi, A.; Hajiramezanali, M.; Amanlou, M. Application of radiolabeled peptides in tumor imaging and therapy. Life Sci. 2020, 258, 118206. [Google Scholar] [CrossRef] [PubMed]
  2. Abbasi Gharibkandi, N.; Conlon, J.M.; Hosseinimehr, S.J. Strategies for improving stability and pharmacokinetic characteristics of radiolabeled peptides for imaging and therapy. Peptides 2020, 133, 170385. [Google Scholar] [CrossRef] [PubMed]
  3. Eychenne, R.; Bouvry, C.; Bourgeois, M.; Loyer, P.; Benoist, E.; Lepareur, N. Overview of Radiolabeled Somatostatin Analogs for Cancer Imaging and Therapy. Molecules 2020, 25, 4012. [Google Scholar] [CrossRef] [PubMed]
  4. Rizvi, S.F.A.; Naqvi, S.A.R.; Roohi, S.; Sherazi, T.A.; Rasheed, R. 177Lu-DOTA-coupled minigastrin peptides: Promising theranostic agents in neuroendocrine cancers. Mol. Biol. Rep. 2018, 45, 1759–1767. [Google Scholar] [CrossRef]
  5. Melis, M.; Krenning, E.P.; Bernard, B.F.; Barone, R.; Visser, T.J.; de Jong, M. Localisation and mechanism of renal retention of radiolabelled somatostatin analogues. Eur. J. Nucl. Med. Mol. Imaging. 2005, 32, 1136–1143. [Google Scholar] [CrossRef]
  6. Melis, M.; Krenning, E.P.; Bernard, B.F.; de Visser, M.; Rolleman, E.; de Jong, M. Renal uptake and retention of radiolabeled somatostatin, bombesin, neurotensin, minigastrin and CCK analogues: Species and gender differences. Nucl. Med. Biol. 2007, 34, 633–641. [Google Scholar] [CrossRef]
  7. Arano, Y. Renal brush border strategy: A developing procedure to reduce renal radioactivity levels of radiolabeled polypeptides. Nucl. Med. Biol. 2021, 92, 149–155. [Google Scholar] [CrossRef]
  8. Barone, R.; Van Der Smissen, P.; Devuyst, O.; Beaujean, V.; Pauwels, S.; Courtoy, P.J.; Jamar, F. Endocytosis of the somatostatin analogue, octreotide, by the proximal tubule-derived opossum kidney (OK) cell line. Kidney Int. 2005, 67, 969–976. [Google Scholar] [CrossRef]
  9. Vegt, E.; de Jong, M.; Wetzels, J.F.; Masereeuw, R.; Melis, M.; Oyen, W.J.; Gotthardt, M.; Boerman, O.C. Renal toxicity of radiolabeled peptides and antibody fragments: Mechanisms, impact on radionuclide therapy, and strategies for prevention. J. Nucl. Med. 2010, 51, 1049–1058. [Google Scholar] [CrossRef]
  10. Lash, L.H.; Shivnani, A.; Mai, J.; Chinnaiyan, P.; Krause, R.J.; Elfarra, A.A. Renal cellular transport, metabolism, and cytotoxicity of S-(6-purinyl)glutathione, a prodrug of 6-mercaptopurine, and analogues. Biochem. Pharmacol. 1997, 54, 1341–1349. [Google Scholar] [CrossRef]
  11. Jones, D.P.; Sundby, G.B.; Ormstad, K.; Orrenius, S. Use of isolated kidney cells for study of drug metabolism. Biochem. Pharmacol. 1979, 28, 929–935. [Google Scholar] [CrossRef] [PubMed]
  12. Racusen, L.C.; Monteil, C.; Sgrignoli, A.; Lucskay, M.; Marouillat, S.; Rhim, J.G.; Morin, J.P. Cell lines with extended in vitro growth potential from human renal proximal tubule: Characterization, response to inducers, and comparison with established cell lines. J. Lab. Clin. Med. 1997, 129, 318–329. [Google Scholar] [CrossRef] [PubMed]
  13. Klaassen, C.D.; Aleksunes, L.M. Xenobiotic, bile acid, and cholesterol transporters: Function and regulation. Pharmacol. Rev. 2010, 62, 1–96. [Google Scholar] [CrossRef] [PubMed]
  14. Elsakka, E.G.E.; Mokhtar, M.M.; Hegazy, M.; Ismail, A.; Doghish, A.S. Megalin, a multi-ligand endocytic receptor, and its participation in renal function and diseases: A review. Life Sci. 2022, 308, 120923. [Google Scholar] [CrossRef] [PubMed]
  15. Eshbach, M.L.; Weisz, O.A. Receptor-Mediated Endocytosis in the Proximal Tubule. Annu. Rev. Physiol. 2017, 79, 425–448. [Google Scholar] [CrossRef] [PubMed]
  16. Christensen, E.I.; Birn, H.; Storm, T.; Weyer, K.; Nielsen, R. Endocytic receptors in the renal proximal tubule. Physiology 2012, 27, 223–236. [Google Scholar] [CrossRef] [PubMed]
  17. Weyer, K.; Nielsen, R.; Petersen, S.V.; Christensen, E.I.; Rehling, M.; Birn, H. Renal uptake of 99mTc-dimercaptosuccinic acid is dependent on normal proximal tubule receptor-mediated endocytosis. J. Nucl. Med. 2013, 54, 159–165. [Google Scholar] [CrossRef] [PubMed]
  18. Blaufox, M.D. Transport of 99mTc-MAG3 via rat renal organic anion. J. Nucl. Med. 2004, 45, 86–88. [Google Scholar]
  19. Cihlo, J.; Melicharová, L.; Petrik, M.; Laznickova, A.; Laznicek, M. Comparison of 111In-DOTA-NOC and 111I-DOTA-TATE distribution in the target and dose-limiting tissues: Conflicting results in vitro and in vivo. Anticancer. Res. 2008, 28, 2189–2195. [Google Scholar]
  20. Trejtnar, F.; Laznicek, M.; Laznickova, A.; Kopecky, M.; Petrik, M.; Béhé, M.; Schmidt, J.; Maecke, H.; Maina, T.; Nock, B. Biodistribution and elimination characteristics of two 111In-labeled CCK-2/gastrin receptor-specific peptides in rats. Anticancer. Res. 2007, 27, 907–912. [Google Scholar]
  21. Melicharova, L.; Laznickova, A.; Laznicek, M. Preclinical evaluation of gastrin derivatives labelled with 111In: Radiolabelling, affinity profile and pharmacokinetics in rats. Biomed. Pap. Med. Fac. Univ. Palacky. Olomouc. Czech. Repub. 2014, 158, 544–551. [Google Scholar] [CrossRef]
  22. Masters, J.R.W. Cell line misidentification: The beginning of the end. Nat. Rev. Cancer 2010, 10, 441–448. [Google Scholar]
  23. Hilgendorf, C.; Ahlin, G.; Seithel, A.; Artursson, P.; Ungell, A.L.; Karlsson, J. Expression of thirty-six drug transporter genes in human intestine, liver, kidney, and organotypic cell lines. Drug Metab. Dispos. 2007, 35, 1333–1340. [Google Scholar] [CrossRef] [PubMed]
  24. Ahlin, G.; Hilgendorf, C.; Karlsson, J.; Szigyarto, C.A.; Uhlén, M.; Artursson, P. Endogenous gene and protein expression of drug-transporting proteins in cell lines routinely used in drug discovery programs. Drug Metab. Dispos. 2009, 37, 2275–2283. [Google Scholar] [CrossRef] [PubMed]
  25. Pietruck, F.; Kuhlmann, M.K.; Lange, B.; Feldkamp, T.; Herget-Rosenthal, S.; Rauen, U.; Burkhardt, G.; Kohler, H.; Philipp, T.; Kribben, A. Effect of quercetin on hypoxic injury in freshly isolated rat proximal tubules. J. Lab. Clin. Med. 2003, 142, 106–112. [Google Scholar] [CrossRef] [PubMed]
  26. Nesslany, F.; Zennouche, N.; Simar-Meintières, S.; Talahari, I.; Nkili-Mboui, E.N.; Marzin, D. In vivo Comet assay on isolated kidney cells to distinguish genotoxic carcinogens from epigenetic carcinogens or cytotoxic compounds. Mutat. Res. 2007, 630, 28–41. [Google Scholar] [CrossRef] [PubMed]
  27. Engbersen, R.; Masereeuw, R.; van Gestel, M.A.; van der Logt, E.M.; Smits, P.; Russel, F.G. Glibenclamide depletes ATP in renal proximal tubular cells by interfering with mitochondrial metabolism. Br. J. Pharmacol. 2005, 145, 1069–1075. [Google Scholar] [CrossRef]
  28. Shaw, S.; Marples, D. A rat kidney tubule suspension for the study of vasopressin-induced shuttling of AQP2 water channels. Am. J. Physiol. Renal. Physiol. 2002, 283, F1160–F1166. [Google Scholar] [CrossRef]
  29. Visarius, T.M.; Putt, D.A.; Schare, J.M.; Pegouske, D.M.; Lash, L.H. Pathways of glutathione metabolism and transport in isolated proximal tubular cells from rat kidney. Biochem. Pharmacol. 1996, 52, 259–272. [Google Scholar] [CrossRef]
  30. Juul, T.; Palm, F.; Nielsen, P.M.; Bertelsen, L.B.; Laustsen, C. Ex vivo hyperpolarized MR spectroscopy on isolated renal tubular cells: A novel technique for cell energy phenotyping. Magn. Reason. Med. 2017, 78, 457–461. [Google Scholar] [CrossRef]
  31. Haenen, H.E.; Rietjens, I.M.; Vervoort, J.; Temmink, J.H.; van Bladeren, P.J. In vitro metabolism of 5-fluoro-2-glutathionyl-nitrobenzene by kidney proximal tubular cells studied by 19F-NMR. Chem. Biol. Interact. 1995, 98, 97–112. [Google Scholar] [CrossRef] [PubMed]
  32. Lash, L.H.; Putt, D.A.; Cai, H. Drug metabolism enzyme expression and activity in primary cultures of human proximal tubular cells. Toxicology 2008, 244, 56–65. [Google Scholar] [CrossRef]
  33. Trejtnar, F.; Novy, Z.; Petrik, M.; Laznickova, A.; Melicharova, L.; Vankova, M.; Laznicek, M. In vitro comparison of renal handling and uptake of two somatostatin receptor-specific peptides labeled with indium-111. Ann. Nucl. Med. 2008, 22, 859–867. [Google Scholar] [CrossRef] [PubMed]
  34. Stolniceanu, C.R.; Nistor, I.; Bilha, S.C.; Constantin, V.; Simona, V.; Matovic, M.; Stefanescu, C.; Covic, A. Nephrotoxicity/renal failure after therapy with 90Yttrium- and 177Lutetium-radiolabeled somatostatin analogs in different types of neuroendocrine tumors: A systematic review. Nucl. Med. Commun. 2020, 41, 601–617. [Google Scholar] [CrossRef] [PubMed]
  35. Zhai, X.Y.; Nielsen, R.; Birn, H.; Drumm, K.; Mildenberger, S.; Freudinger, R.; Moestrup, S.K.; Verroust, P.J.; Christensen, E.I.; Gekle, M. Cubilin- and megalin-mediated uptake of albumin in cultured proximal tubule cells of opossum kidney. Kidney Int. 2000, 58, 1523–1533. [Google Scholar] [CrossRef]
  36. Christensen, E.I.; Nielsen, R. Role of megalin and cubilin in renal physiology and pathophysiology. Rev. Physiol. Biochem. Pharmacol. 2007, 158, 1–22. [Google Scholar]
  37. Donato, M.T.; Lahoz, A.; Castell, J.V.; Gómez-Lechón, M.J. Cell lines: A tool for in vitro drug metabolism studies. Curr. Drug Metab. 2008, 9, 1–11. [Google Scholar]
  38. Behrens, I.; Kamm, W.; Dantzig, A.H.; Kissel, T. Variation of peptide transporter (PepT1 and HPT1) expression in Caco-2 cells as a function of cell origin. J. Pharm. Sci. 2004, 93, 1743–1754. [Google Scholar] [CrossRef]
  39. Aiba, T.; Susa, M.; Fukumori, S.; Hashimoto, Y. The effects of culture conditions on CYP3A4 and MDR1 mRNA induction by 1,25-dihydroxyvitamin D3 in human intestinal cell lines, Caco-2 and LS180. Drug Metab. Pharmacokinet. 2005, 20, 268–274. [Google Scholar] [CrossRef]
  40. Odera, K.; Goto, S.; Takahashi, R. Age-related change of endocytic receptors megalin and cubilin in the kidney in rats. Biogerontology 2007, 8, 505–515. [Google Scholar] [CrossRef]
  41. Zheng, G.; Bachinsky, D.R.; Stamenkovic, I.; Strickland, D.K.; Brown, D.; Andres, G.; McCluskey, R.T. Organ distribution in rats of two members of the low-density lipoprotein receptor gene family, gp330 and LRP/alpha 2MR, and the receptor-associated protein (RAP). J. Histochem. Cytochem. 1994, 42, 531–542. [Google Scholar] [CrossRef] [PubMed]
  42. Verroust, P.J.; Birn, H.; Nielsen, R.; Kozyraki, R.; Christensen, E.I. The tandem endocytic receptors megalin and cubilin are important proteins in renal pathology. Kidney Int. 2002, 62, 745–756. [Google Scholar] [CrossRef] [PubMed]
  43. Benešová, M.; Guzik, P.; Deberle, L.M.; Busslinger, S.D.; Landolt, T.; Schibli, R.; Müller, C. Design and Evaluation of Novel Albumin-Binding Folate Radioconjugates: Systematic Approach of Varying the Linker Entities. Mol. Pharm. 2022, 19, 963–973. [Google Scholar] [CrossRef]
  44. Garousi, J.; Vorobyeva, A.; Altai, M. Influence of Several Compounds and Drugs on the Renal Uptake of Radiolabeled Affibody Molecules. Molecules 2020, 25, 2673. [Google Scholar] [CrossRef] [PubMed]
  45. Geenen, L.; Nonnekens, J.; Konijnenberg, M.; Baatout, S.; De Jong, M.; Aerts, A. Overcoming nephrotoxicity in peptide receptor radionuclide therapy using [177Lu]Lu-DOTA-TATE for the treatment of neuroendocrine tumours. Nucl. Med. Biol. 2021, 102–103, 1–11. [Google Scholar] [CrossRef]
  46. Zhang, M.; Jacobson, O.; Kiesewetter, D.O.; Ma, Y.; Wang, Z.; Lang, L.; Tang, L.; Kang, F.; Deng, H.; Yang, W.; et al. Improving the Theranostic Potential of Exendin 4 by Reducing the Renal Radioactivity through Brush Border Membrane Enzyme-Mediated Degradation. Bioconjug. Chem. 2019, 30, 1745–1753. [Google Scholar] [CrossRef] [PubMed]
  47. Bendre, S.; Zhang, Z.; Kuo, H.T.; Rousseau, J.; Zhang, C.; Merkens, H.; Roxin, Á.; Bénard, F.; Lin, K.S. Evaluation of Met-Val-Lys as a Renal Brush Border Enzyme-Cleavable Linker to Reduce Kidney Uptake of 68Ga-Labeled DOTA-Conjugated Peptides and Peptidomimetics. Molecules 2020, 25, 3854. [Google Scholar] [CrossRef]
  48. Liu, W.; Yu, W.R.; Carling, T.; Juhlin, C.; Rastad, J.; Ridefelt, P.; Akerström, G.; Hellman, P. Regulation of gp330/megalin expression by vitamins A and D. Eur. J. Clin. Invest. 1998, 28, 100–107. [Google Scholar] [CrossRef]
  49. Demeule, M.; Jodoin, J.; Beaulieu, E. Dexamethasone modulation of multidrug transporters in normal tissues. FEBS Lett. 1999, 442, 208–214. [Google Scholar] [CrossRef]
  50. Donner, M.G.; Keppler, D. Up-regulation of basolateral multidrug resistence protein 3 (Mrp3) in cholestatic rat liver. Hepatology 2001, 34, 351–359. [Google Scholar] [CrossRef]
  51. Payen, L.; Courtois, A.; Campion, J.P. Characterization and inhibition by a wide range of xenobiotics of organic anion excretion by primary human hepatocytes. Biochem. Pharmacol. 2000, 60, 1967–1975. [Google Scholar] [CrossRef] [PubMed]
  52. Kubitz, R.; Warskulat, U.; Schmitt, M. Dexamethasone- and osmolarity—Dependent expression of the multidrug resistence protein 2 in cultured rat hepatocytes. Biochem. J. 1999, 340, 585–591. [Google Scholar] [CrossRef] [PubMed]
  53. Smith, P.K.; Krohn, R.I.; Hermanson, G.T.; Mallia, A.K.; Gartner, F.H.; Provenzano, M.D.; Fujimoto, E.K.; Goeke, N.M.; Olson, B.J.; Klenk, D.C. Measurement of protein using bicinchoninic acid. Anal Biochem. 1985, 150, 76–85. [Google Scholar] [CrossRef] [PubMed]
  54. Ivanyi, B.; Olsen, T.S. Immunohistochemical identification of tubular segments in percutaneous renal biopsies. Histochemistry 1991, 95, 351–356. [Google Scholar] [CrossRef] [PubMed]
  55. Hill, M.S.; Ruiz, A.; Gomez, L.M.; Miller, J.M.; Berman, N.E.; Stephens, E.B. APOBEC3G expression is restricted to epithelial cells of the proximal convoluted tubules and is not expressed in the glomeruli of macaques. J. Histochem. Cytochem. 2007, 55, 63–70. [Google Scholar] [CrossRef] [PubMed]
  56. Dekker, B.G.; Arts, C.J.; De Ligny, C.L. Gel-chromatographic analysis of 99mTc-labeled human serum albumin prepared with Sn(II) as the reductant. Int. J. Appl. Radiat. Isot. 1982, 33, 1351–1357. [Google Scholar] [CrossRef] [PubMed]
Pharmaceuticals 16 00696 g001 550
Figure 1. Western blot analysis of megalin expression in experimental renal cellular models of OK, LLC-PK1, and isolated rat cells compared to megalin expression in the porcine kidney, rat kidney, and human placental cells.
Figure 1. Western blot analysis of megalin expression in experimental renal cellular models of OK, LLC-PK1, and isolated rat cells compared to megalin expression in the porcine kidney, rat kidney, and human placental cells.
Pharmaceuticals 16 00696 g001
Pharmaceuticals 16 00696 g002 550
Figure 2. Colocalization of megalin and PHA-E in natural rat kidney tissue. Slight PHA-E staining is visible in the glomeruli. However, colocalization of megalin (green) and PHA-E (red) is observed only in the proximal tubules. By contrast, no staining is visible in the distal tubules (asterisk). DAPI was used for nuclei staining. Original magnification was 400×.
Figure 2. Colocalization of megalin and PHA-E in natural rat kidney tissue. Slight PHA-E staining is visible in the glomeruli. However, colocalization of megalin (green) and PHA-E (red) is observed only in the proximal tubules. By contrast, no staining is visible in the distal tubules (asterisk). DAPI was used for nuclei staining. Original magnification was 400×.
Pharmaceuticals 16 00696 g002
Pharmaceuticals 16 00696 g003 550
Figure 3. Colocalization of megalin and PHA-E in isolated rat kidney cells. Colocalization of megalin (green) and PHA-E (red) is evident in the proximal tubule cells (arrows). DAPI was used for nuclei staining. Original magnification was 400×.
Figure 3. Colocalization of megalin and PHA-E in isolated rat kidney cells. Colocalization of megalin (green) and PHA-E (red) is evident in the proximal tubule cells (arrows). DAPI was used for nuclei staining. Original magnification was 400×.
Pharmaceuticals 16 00696 g003
Pharmaceuticals 16 00696 g004 550
Figure 4. Colocalization of megalin and PNA in isolated rat kidney cells. No colocalization of megalin (green) and PNA (red) was detected in rat kidney cells. Megalin staining is visible only. Original magnification was 400×.
Figure 4. Colocalization of megalin and PNA in isolated rat kidney cells. No colocalization of megalin (green) and PNA (red) was detected in rat kidney cells. Megalin staining is visible only. Original magnification was 400×.
Pharmaceuticals 16 00696 g004
Pharmaceuticals 16 00696 g005 550
Figure 5. Accumulation of somatostatin receptor-specific analogs [111In]In-DOTA-TATE (In-DOTA-TATE) and [111In]In-DOTA-NOC (In-DOTA-NOC) in different renal cellular experimental models (incubation time = 30 min).
Figure 5. Accumulation of somatostatin receptor-specific analogs [111In]In-DOTA-TATE (In-DOTA-TATE) and [111In]In-DOTA-NOC (In-DOTA-NOC) in different renal cellular experimental models (incubation time = 30 min).
Pharmaceuticals 16 00696 g005
Pharmaceuticals 16 00696 g006 550
Figure 6. Comparative analysis of the active and passive cellular accumulation of selected radiolabeled compounds (n = 4) using rat-isolated renal cells. Accumulation at 37 °C is considered 100%. (Lu-DOTA-TATE = [177Lu]Lu-DOTA-TATE; Lu-DOTA-NOC = [177Lu]Lu-DOTA-NOC; Tc-albumin = [99mTc]Tc-albumin; Tc-DMSA = [99mTc]Tc-DMSA; Tc-MAG3 = [99mTc]Tc-MAG3).
Figure 6. Comparative analysis of the active and passive cellular accumulation of selected radiolabeled compounds (n = 4) using rat-isolated renal cells. Accumulation at 37 °C is considered 100%. (Lu-DOTA-TATE = [177Lu]Lu-DOTA-TATE; Lu-DOTA-NOC = [177Lu]Lu-DOTA-NOC; Tc-albumin = [99mTc]Tc-albumin; Tc-DMSA = [99mTc]Tc-DMSA; Tc-MAG3 = [99mTc]Tc-MAG3).
Pharmaceuticals 16 00696 g006
Table
Table 1. Comparison of radiopeptide uptake in isolated rat cells (%D/106 cells) and in rat kidneys in vivo (%D/g).
Table 1. Comparison of radiopeptide uptake in isolated rat cells (%D/106 cells) and in rat kidneys in vivo (%D/g).
RadiopeptideIn VitroIn Vivo
[111In]In-DOTA-TATE0.36 ± 0.103.08 ± 0.42 [19]
[111In]In-DOTA-NOC0.75 ± 0.092.84 ± 0.28 [19]
[111In]In-DTPA-MG02.52 ± 0.5826.4 ± 14.6 [20]
[111In]In-DOTA-MG110.16 ± 0.150.84 ± 0.35 [21]
[111In]In-DOTA-MG450.26 ± 0.161.53 ± 1.35 [21]
[111In]In-DOTA-MG470.30 ± 0.031.84 ± 1.40 [21]
Table
Table 2. Comparison of [99mTc]Tc-albumin uptake in young (grown for 6 h) and older (grown for 3 days) LLC-PK1 cells and isolated rat renal cells (mean ± S.D.; n = 4).
Table 2. Comparison of [99mTc]Tc-albumin uptake in young (grown for 6 h) and older (grown for 3 days) LLC-PK1 cells and isolated rat renal cells (mean ± S.D.; n = 4).
Young LLC-PK1 Cells Older LLC-PK1 CellsRat Renal Cells
Cellular uptake
(%D/106 cells/30 min)		0.036 ± 0.0060.083 ± 0.015 ★2.188 ± 0.411 §
★ Statistically significant differences in younger LLC-PK1 cells at p < 0.05; § significant differences in older LCC-PK1 cells at p < 0.05.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Barta, P.; Nachtigal, P.; Maixnerova, J.; Zemankova, L.; Trejtnar, F. Validation of Freshly Isolated Rat Renal Cells as a Tool for Preclinical Assessment of Radiolabeled Receptor-Specific Peptide Uptake in the Kidney. Pharmaceuticals 2023, 16, 696. https://doi.org/10.3390/ph16050696

AMA Style

Barta P, Nachtigal P, Maixnerova J, Zemankova L, Trejtnar F. Validation of Freshly Isolated Rat Renal Cells as a Tool for Preclinical Assessment of Radiolabeled Receptor-Specific Peptide Uptake in the Kidney. Pharmaceuticals. 2023; 16(5):696. https://doi.org/10.3390/ph16050696

Chicago/Turabian Style

Barta, Pavel, Petr Nachtigal, Jana Maixnerova, Lenka Zemankova, and Frantisek Trejtnar. 2023. "Validation of Freshly Isolated Rat Renal Cells as a Tool for Preclinical Assessment of Radiolabeled Receptor-Specific Peptide Uptake in the Kidney" Pharmaceuticals 16, no. 5: 696. https://doi.org/10.3390/ph16050696

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop